Immuneering Corporation

NASDAQ:IMRX

Biotechnology

Healthcare
$3.50 -0.14%

-$0.01 today

Market cap
$226.67M
Beta
0.38
P/E (TTM)
-3.6
EPS (TTM)
-$1.24
52W Low $2.29High $10.08

Volume 0.73M

Average 1.38M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$45.34M

FY 2025 · Annual

Investing Cash Flow

-$88.74M

FY 2025 · Annual

Financing Cash Flow

$226.58M

FY 2025 · Annual

+4172.3% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(33.54M)(50.51M)(53.47M)(61.04M)(56.02M)
Depreciation & Amortization159.07K796.79K352.08K385.07K698.89K
Deferred Income Tax(307.49K)0000
Stock-Based Compensation1.8M05.73M6.5M0
Change in Working Capital900.42K1.72M(974.64K)(925.38K)3.82M
Accounts Receivables279.71K233.62K12.42K00
Inventory00000
Accounts Payables(130.4K)1.76M(1.11M)(112.14K)(400.8K)
Other Working Capital751.1K(276.56K)119.84K(813.24K)4.22M
Other Non-Cash Items130.24K3.9M(601.59K)75.98K6.16M
Operating Cash Flow(30.85M)(44.1M)(48.97M)(55M)(45.34M)
Capital Expenditures(60.79K)(742.49K)(342.75K)(84.88K)(142.23K)
Acquisitions (Net)70.35K0000
Purchases of Investments(75.63M)(50.1M)(44.66M)(5.41M)(88.6M)
Sales of Investments75.62M92.68M52.3M31.93M0
Other Investing Activities(75.62M)000247
Investing Cash Flow(75.62M)41.83M7.3M26.43M(88.74M)
Debt Repayment00000
Common Stock Issued120.32M19K28.2M4.24M226.58M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(842.76K)0241.07K1.07M(147)
Financing Cash Flow144.26M19K28.44M5.3M226.58M
Effect of Forex Changes00000
Net Change in Cash37.8M(2.25M)(13.23M)(23.26M)92.5M
Free Cash Flow(30.91M)(44.84M)(49.31M)(55.08M)(45.49M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$56.0M
+ D&A$698.9K
+ Stock-Based Comp$0
+ Deferred Tax$0
+ Working Capital$3.8M
+ Other Non-Cash$6.2M
= Operating Cash Flow-$45.3M
- Capex-$142.2K
= Free Cash Flow-$45.5M

Analysis

FY2025 free cash flow is -$45.5M. FCF conversion is 81.2% of net income. Operating cash flow was -$45.3M, with capex of -$142.2K. The largest bridge item is Other Non-Cash at $6.2M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportNov 9, 2026
4Statement of changes in beneficial ownershipNov 9, 2026
3Initial statement of beneficial ownershipNov 9, 2026
10-QQuarterly reportOct 29, 2026
8-KCurrent reportOct 29, 2026

Does IMRX generate free cash flow?

Immuneering Corporation (IMRX) generated -$45.49M of free cash flow in fiscal 2025.

How much operating cash flow does IMRX produce?

Operating cash flow was -$45.34M, before capital expenditures of $142,225.00.